Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...

Merck has development and commercialization agreements with AstraZeneca, Daiichi Sankyo, and LaNova. It also has collaboration agreements with Bayer, Eisai, Moderna, and Ridgeback Biotherapeutics.

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

The results suggest that AZ and Daiichi Sankyo could be in line for ... NSCLC in combination with Keytruda in a trial sponsored by Merck. AZ licensed rights to DS-1062 in July 2020 for $1 billion ...

Merck & Co., Inc. operates as a healthcare company ... vIt has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates, which include patritumab ...

Vandana Singh Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab ...

Magnificent Seven stocks. Big Tech's runaway growth created gains, but headwinds are forming and some observers doubt the Mag ...

It is well recognized that lowering low-density lipoprotein (LDL) cholesterol can substantially reduce coronary heart disease (CHD)-related morbidity and mortality. The magnitude of event ...